サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1657248

新型コロナウイルス感染症（COVID-19）最新治療の世界市場:2034年までの機会と戦略

Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 302 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
新型コロナウイルス感染症（COVID-19）最新治療の世界市場:2034年までの機会と戦略
出版日: 2025年02月17日
発行: The Business Research Company
ページ情報: 英文 302 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

新型コロナウイルス感染症（COVID-19）最新治療とは、COVID-19の症状を管理・治療し、ウイルス量を減少させ、入院や死亡などの重篤な転帰を予防するために使用される様々な医薬品治療および治療介入を指します。これらの治療法は、SARS-CoV-2（重症急性呼吸器症候群コロナウイルス2）ウイルス、関連する炎症、疾患によって引き起こされる合併症を標的とし、回復率の向上と長期的な健康への影響の最小化を目指しています。

新型コロナウイルス感染症（COVID-19）最新治療市場は、ウイルスに感染した患者の広範な層（軽度、中等度、重度の症例を含む）によって利用されるコロナウイルス（COVID-19）最新の治療法の販売を含んでいます。この市場には、法人、個人事業主、またはパートナーシップによる販売が含まれます。これらの治療は、急性期から長期にわたる治療シナリオの両方で採用されており、早期段階での介入から重症患者の高度な治療まで多岐にわたります。これらの治療法は、酸素療法、人工呼吸、その他の重症患者ケアなどの支持療法と併用されることが多く、主力の抗ウイルス薬や抗炎症薬を補完するものです。

世界の新型コロナウイルス感染症（COVID-19）最新治療市場は、2024年には93億6,771万米ドルに減少しました。

臨床試験の拡大

実績期間において、臨床試験の拡大が新型コロナウイルス感染症（COVID-19）最新治療市場の成長を支えました。臨床試験は、新たな治療法の安全性と有効性を体系的に評価する上で重要な役割を果たし、ヘルスケア提供者と患者の信頼関係を構築します。これらの臨床試験で良好な結果が得られれば、規制当局の承認が得られ、新しい治療法の普及が促進されます。臨床試験、特に第II相および第III相試験の結果は、規制当局が承認プロセスを迅速化するために必要なデータを提供します。このような迅速な承認は、新しい治療法の迅速な導入に貢献し、COVID-19治療の状況を向上させています。例えば、2023年11月、英国を拠点とする協会である英国製薬工業協会（ABPI）が発表した報告書によると、2021年の臨床試験数は394件で、2022年には411件に増加しました。さらに2023年5月、カナダを拠点にライフサイエンスウェビナーやバーチャルイベントの提供を専門とするXtalksによると、2023年5月17日現在、ClinicalTrials.govに登録されている臨床試験は45万2,604件です。登録された臨床試験のうち6万4,838件が積極的に参加者を求めており、2021年には36万5,000件が登録されました。このように、臨床試験の拡大が新型コロナウイルス感染症（COVID-19）最新治療市場の成長を牽引しました。

COVID-19治療のための抗ウイルス薬開発の進歩

新型コロナウイルス感染症（COVID-19）最新治療市場で事業を展開する企業は、患者の進化するニーズに対応し、治療成果を高めるために抗ウイルス薬の開発に注力しています。抗ウイルス薬は、体内でのウイルスの複製と拡散を阻害することによってウイルス感染と闘うために開発された特殊な治療法です。抗ウイルス薬は、ウイルスを標的として独自に調整されています。例えば、2023年5月、米国の製薬会社Pfizer Inc.,は、経口抗ウイルス治療薬パクスロビッドの承認を米国食品医薬品局（FDA）から取得しました。この薬剤は、入院や死亡を含む重篤な転帰のリスクが高い軽度から中等度のCOVID-19の成人の治療に使用されます。臨床試験の結果、パクスロビドは症状発現から5日以内に投与した場合、入院または死亡のリスクを約86％有意に減少させることが示されています。

世界の新型コロナウイルス感染症（COVID-19）最新治療市場は、多くの大手企業が参入しています。同市場における上位10社の競合企業は、2023年の市場全体の40.4%を占めています。

Business Research Companyの調査レポート「新型コロナウイルス感染症（COVID-19）最新治療の世界市場：2034年までの事業機会と戦略」は、戦略担当者、マーケティング担当者、上級管理職向けに、COVID-19のロックダウンから立ち上がる新型コロナウイルス感染症（COVID-19）最新治療の世界市場を評価するために必要な重要情報を提供しています。

購入の理由

15地域をカバーするこの市場に関する最も包括的なレポートにより、真に世界的な視点を得ることができます。市場がコロナウイルスによってどのような影響を受けているのか、また、ウイルスの影響が和らぐにつれて市場がどのように浮上し、成長する可能性があるのかを理解できます。現地のデータと分析に基づき、地域別・国別戦略を策定します。投資の対象となる成長セグメントを特定します。予測データと市場を形成する促進要因と動向を活用し、競合他社を凌駕します。最新の市場調査結果に基づいて顧客を理解できます。主要な競合他社とのパフォーマンスの比較主要データセット間の関係を活用し、優れた戦略を立てることができます。信頼性の高い高品質のデータと分析により、社内外のプレゼンテーションをサポートするのに適しています。

新型コロナウイルス感染症（COVID-19）最新治療で最大かつ急成長している市場はどこか？経済全体、人口動態、他の類似市場との関連は？今後どのような力が市場を形成していくのか？この調査レポートは新型コロナウイルス感染症（COVID-19）最新治療市場の世界市場の調査報告書です。

当レポートでは、市場の特徴、規模と成長、セグメンテーション、地域と国内訳、競合情勢、市場シェア、当市場の動向と戦略について記載しています。市場の実績から、地域別の市場成長を予測しています。また、市場をより広範な新型コロナウイルス感染症（COVID-19）最新治療市場の文脈に位置付け、他市場との比較も行っています。

当レポートは以下の章をカバーしています。

導入と市場セグメンテーション-薬剤タイプ別、投与経路別、エンドユーザー別など、市場セグメンテーションを簡単に紹介し、定義や解説を加えています。世界の主な動向-世界市場を形成する主な動向にハイライトを当てます。また、今後の市場開拓についても取り上げます。 マクロ経済シナリオ-COVID-19パンデミックの影響、ロシア・ウクライナ戦争の影響、インフレ上昇の世界市場および地域市場への影響を分析し、COVID-19の最新治療市場のビジネスに戦略的洞察を提供します。

世界の市場規模と成長-世界の実績（2019～2024年）および予測（2024～2029年、2034年）市場価値、実績期間および予測期間における市場成長を支え、抑制する促進要因と抑制要因を掲載しています。 地域別・国別分析-地域別・国別の過去（2019～2024年）および予測（2024～2029年、2034年）市場価値と成長率、市場シェア比較を掲載しています。市場セグメンテーション-市場における薬剤タイプ別、投与経路別、エンドユーザー別の市場価値（2019～2024年）（2024～2029年、2034年）と各セグメント別の分析を収録しています。地域別の過去（2019～2024年）、予測（2024～2029年）、（2029～2034年）市場価値と成長率、市場シェア比較を掲載しています。 地域別市場規模と成長率-地域別市場規模（2024年）、地域内各国の過去（2019～2024年）および予測（2024～2029年、2034F）市場価値と成長率、市場シェア比較を掲載しています。アジア太平洋、西欧、東欧、北米、南米、中東・アフリカの全地域と各地域内の主要国に関する情報を掲載しています。

競合情勢-市場の競合情勢の詳細、推定市場シェア、主要企業の企業プロファイルを掲載しています。その他の主要企業および革新的企業-市場におけるその他の主要企業および革新的企業の企業プロファイルの詳細、競合ベンチマーキング-市場の主要企業間の財務比較についての概要を掲載しています。

競合ダッシュボード-主要プレーヤーの競合ダッシュボードの概要、主要なM&A-レポートでカバーしている市場における最近のM&Aに関する情報を掲載しています。本セクションでは、近年の市場を形成したM&Aに関する主要な財務情報を提供します。

市場セグメンテーション-調査結果に基づく市場機会と戦略について、国やセグメントごとの成長機会やその市場で取るべき戦略などの情報を交えて解説しています。 結論・提言-このセクションでは、新型コロナウイルス感染症（COVID-19）最新治療プロバイダーに対する製品/サービス提供地域拡大、マーケティング戦略、ターゲットグループに関する提言が記載されています。

付録-このセクションには、対象NAICSコード、略語、当レポートで使用した通貨コードの詳細が含まれています。

対象市場

  • 薬剤タイプ別：抗ウイルス薬、モノクローナル抗体（Mabs）、副腎皮質ステロイド、サプリメント、抗マラリア薬、インターフェロンおよびインターロイキン阻害薬、その他の抗感染薬、その他
  • 投与経路別：経口、静脈内
  • エンドユーザー別：病院、クリニック、在宅医療、その他エンドユーザー
  • 注目企業：Gilead Sciences, Inc、Merck &Co、Regeneron Pharmaceuticals, Inc、F. Hoffmann-La Roche AG、Ipca Laboratories Limited
  • 国：中国、オーストラリア、インド、インドネシア、日本、韓国、米国、カナダ、ブラジル、フランス、ドイツ、英国、イタリア、スペイン、ロシア
  • 対象地域：アジア太平洋、西欧、東欧、北米、南米、中東、アフリカ
  • 時系列：
  • データ：関連市場に対する市場規模および成長率、GDP比率、一人当たり支出、新型コロナウイルス感染症（COVID-19）最新治療指標比較
  • データ区分：国および地域の過去および予測データ、競合他社の市場シェア、市場セグメント
  • ソーシングおよび参照：当レポート中のデータおよび分析は、エンドノートを用いています。

目次

第1章 エグゼクティブサマリー

  • 新型コロナウイルス感染症（COVID-19）最新治療-市場の魅力とマクロ経済情勢

第2章 目次

第3章 表一覧

第4章 図一覧

第5章 レポート構成

第6章 市場の特徴

  • 一般的な市場の定義
  • 概要
  • 新型コロナウイルス感染症（COVID-19）最新治療：市場定義とセグメンテーション
  • 市場セグメンテーション：薬剤タイプ別
    • 抗ウイルス薬
    • モノクローナル抗体（Mabs）
    • コルチコステロイド
    • サプリメント
    • 抗マラリア
    • インターフェロンとインターロイキン阻害剤
    • その他の感染症予防
    • その他
  • 市場セグメンテーション：投与経路別
    • 経口
    • 静脈内
  • 市場セグメンテーション：エンドユーザー別
    • 病院
    • クリニック
    • ホームケア
    • その他

第7章 主要な市場動向

  • 戦略的投資がCOVID-19治療市場の成長を牽引
  • COVID-19治療のための抗ウイルス薬開発の進歩
  • ヘルスケアのアクセシビリティを変革するデジタルソリューション

第8章 新型コロナウイルス感染症（COVID-19）最新治療市場：マクロ経済シナリオ

  • COVID-19の影響：新型コロナウイルス感染症（COVID-19）最新治療市場
  • ウクライナ戦争の影響：新型コロナウイルス感染症（COVID-19）最新治療市場
  • 高インフレの影響：新型コロナウイルス感染症（COVID-19）最新治療市場

第9章 世界の市場規模と成長

  • 市場規模
  • 市場成長実績、2019～2024年
    • 市場促進要因、2019～2024年
    • 市場抑制要因、2019～2024年年
  • 市場成長予測、2024～2029年、2034年
    • 市場促進要因、2024～2029年
    • 市場抑制要因、2024～2029年

第10章 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：セグメンテーション

  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：薬剤タイプ別、実績と予測、2019～2024年、2029年、2034年
  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：投与経路別、実績と予測、2019～2024年、2029年、2034年
  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：エンドユーザー別、実績と予測、2019～2024年、2029年、2034年

第11章 新型コロナウイルス感染症（COVID-19）最新治療市場：地域・国別分析

  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：地域別、実績と予測、2019～2024年、2029年、2034年
  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場：国別、実績と予測、2019～2024年、2029年、2034年

第12章 アジア太平洋市場

第13章 西欧市場

第14章 東欧市場

第15章 北米市場

第16章 南米市場

第17章 中東市場

第18章 アフリカ市場

第19章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Gilead Sciences, Inc
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc
  • F. Hoffman-La Roche Ltd
  • Ipca Laboratories Limited

第20章 その他の大手企業と革新的企業

  • Zydus Group
  • Sun Pharmaceutical Industries Limited
  • AbbVie Inc
  • Pfizer Inc
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sanofi SA
  • GSK（GlaxoSmithKline）
  • Novavax Inc
  • AstraZeneca
  • Johnson & Johnson
  • Moderna Inc
  • CureVac N.V.
  • Wallace Pharmaceuticals, Inc
  • Clover Biopharmaceuticals Ltd

第21章 競合ベンチマーキング

第22章 競合ダッシュボード

第23章 主要な合併と買収

  • GSK Acquires CureVac
  • FSII-Pardes Biosciences Merger Aims To Enhance COVID-19 Antiviral Therapy Capabilities

第24章 機会と戦略

  • 世界の新型コロナウイルス感染症（COVID-19）最新治療市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第25章 COVID-19最新治療市場、結論・提言

  • 結論
  • 提言
    • 製品
    • 場所
    • 価格
    • プロモーション
    • 人々

第26章 付録

目次
Product Code: o&s1493

coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts.

The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.

The global coronavirus (COVID-19) current therapy market declined to $9,367.71 million in 2024.

Expanding Clinical Trials

During the historic period, the expanding clinical trials supported the growth of coronavirus (COVID-19) current therapy market. Clinical trials play a crucial role in systematically evaluating the safety and efficacy of emerging treatments, which builds trust among healthcare providers and patients. Positive outcomes from these trials support regulatory approvals, facilitating the widespread adoption of new therapies. Results from clinical trials, particularly Phase II and Phase III studies, provide the necessary data for regulatory bodies to expedite approval processes. These accelerated approvals have contributed to the swift introduction of new therapies, enhancing the landscape of COVID-19 treatments. For instance, in November 2023, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, there were 394 trials in 2021; the clinical trial number increased to 411 in 2022. Additionally, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials.gov as of May 17, 2023. 64,838 studies out of the total number that have been registered are actively seeking participants which is an increase of 365,000 registered trials in 2021. Therefore, the expanding clinical trials drove the growth of coronavirus (COVID-19) current therapy market.

Advancements In Antiviral Drug Development For COVID-19 Treatment

Companies operating in the coronavirus (COVID-19) current therapy market are focusing on developing antiviral drugs to address the evolving needs of patients and enhance therapeutic outcomes. Antiviral drugs are specialized treatments developed to combat viral infections by disrupting the replication and spread of viruses within the body. Antiviral drugs are uniquely tailored to target viruses. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for the oral antiviral treatment, PAXLOVID. This drug is used for the treatment of adults with mild-to-moderate COVID-19 who are at high risk of severe outcomes, including hospitalization or death. Clinical studies have shown that PAXLOVID significantly reduces the risk of hospitalization or death by approximately 86% when administered within five days of symptom onset.

The global coronavirus (COVID-19) current therapy market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 40.4% of the total market in 2023.

Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for coronavirus (COVID-19) current therapy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The coronavirus (COVID-19) current therapy market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider coronavirus (COVID-19) current therapy market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug type, by route of administration and by end-user.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the COVID-19 current therapy market.
  • Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug type, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for coronavirus (COVID-19) current therapy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Drug Type: Antivirals; Monoclonal Antibodies (Mabs); Corticosteroid; Supplements; Antimalarial; Interferons And Interleukin Inhibitors; Other Anti Infections; Others
  • 2) By Route Of Administration: Oral; Intravenous
  • 3) By End User: Hospitals; Clinics; Home Care; Other End Users
  • Companies Mentioned: Gilead Sciences, Inc.; Merck & Co; Regeneron Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Ipca Laboratories Limited
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; coronavirus (COVID-19) current therapy indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Coronavirus (COVID-19) Current Therapy - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Coronavirus (COVID-19) Current Therapy Market Definition And Segmentations
  • 6.4 Market Segmentation By Drug Type
    • 6.4.1 Antivirals
    • 6.4.2 Monoclonal Antibodies (Mabs)
    • 6.4.3 Corticosteroid
    • 6.4.4 Supplements
    • 6.4.5 Antimalarial
    • 6.4.6 Interferons And Interleukin Inhibitors
    • 6.4.7 Other Anti Infections
    • 5.4.8 Others
  • 6.5 Market Segmentation By Route Of Administration
    • 6.5.1 Oral
    • 6.5.2 Intravenous
  • 6.6 Market Segmentation By End-User
    • 6.6.1 Hospitals
    • 6.6.2 Clinics
    • 6.6.3 Home Care
    • 6.6.4 Other End-Users

7 Major Market Trends

  • 7.1 Strategic Investments Driving COVID-19 Therapy Market Growth
  • 7.2 Advancements In Antiviral Drug Development For COVID-19 Treatment
  • 7.3 Digital Solutions Transforming Healthcare Accessibility

8 Coronavirus (COVID-19) Current Therapy Market - Macro Economic Scenario

  • 8.1 COVID-19 Impact On The Coronavirus (COVID-19) Current Therapy Market
  • 8.2 Impact Of The War In Ukraine On The Coronavirus (COVID-19) Current Therapy Market
  • 8.3 Impact Of High Inflation On The Coronavirus (COVID-19) Current Therapy Market

9 Global Market Size and Growth

  • 9.1 Market Size
  • 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 9.2.1 Market Drivers 2019 - 2024
    • 9.2.2 Market Restraints 2019- 2024
  • 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 9.3.1 Market Drivers 2024 - 2029
    • 9.3.2 Market Restraints 2024 - 2029

10 Global Coronavirus (COVID-19) Current Therapy Market Segmentation

  • 10.1 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Coronavirus (COVID-19) Current Therapy Market, Regional and Country Analysis

  • 11.1 Global Coronavirus (COVID-19) Current Therapy Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.2 Global Coronavirus (COVID-19) Current Therapy Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

  • 12.1 Summary
    • 12.1.1 Market Overview
    • 12.1.2 Region Information
    • 12.1.3 Market Information
    • 12.1.4 Background Information
    • 12.1.5 Government Initiatives
    • 12.1.6 Regulations
    • 12.1.7 Regulatory Bodies
    • 12.1.8 Major Associations
    • 12.1.9 Taxes Levied
    • 12.1.10 Corporate Tax Structure
    • 12.1.11 Investments
    • 12.1.12 Major Companies
  • 12.2 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.3 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market: Country Analysis
  • 12.6 China Market
  • 12.7 Summary
    • 12.7.1 Market Overview
    • 12.7.2 Country Information
    • 12.7.3 Market Information
    • 12.7.4 Background Information
    • 12.7.5 Government Initiatives
    • 12.7.6 Regulations
    • 12.7.7 Regulatory Bodies
    • 12.7.8 Major Associations
    • 12.7.9 Taxes Levied
    • 12.7.10 Corporate Tax Structure
    • 12.7.11 Investments
    • 12.7.12 Major Companies
  • 12.8 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.9 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 India Market
  • 12.12 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 Japan Market
  • 12.16 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Australia Market
  • 12.20 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Indonesia Market
  • 12.24 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.27 South Korea Market
  • 12.28 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.29 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.30 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

  • 13.1 Summary
    • 13.1.1 Market Overview
    • 13.1.2 Region Information
    • 13.1.3 Market Information
    • 13.1.4 Background Information
    • 13.1.5 Government Initiatives
    • 13.1.6 Regulations
    • 13.1.7 Regulatory Bodies
    • 13.1.8 Major Associations
    • 13.1.9 Taxes Levied
    • 13.1.10 Corporate Tax Structure
    • 13.1.11 Investments
    • 13.1.12 Major Companies
  • 13.2 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.3 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 UK Market
  • 13.6 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.7 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.8 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 Germany Market
  • 13.10 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.11 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.12 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.13 France Market
  • 13.14 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.15 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.16 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.17 Italy Market
  • 13.18 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.19 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.20 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.21 Spain Market
  • 13.22 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.23 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.24 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

  • 14.1 Summary
    • 14.1.1 Market Overview
    • 14.1.2 Region Information
    • 14.1.3 Market Information
    • 14.1.4 Background Information
    • 14.1.5 Government Initiatives
    • 14.1.6 Regulations
    • 14.1.7 Regulatory Bodies
    • 14.1.8 Major Associations
    • 14.1.9 Taxes Levied
    • 14.1.10 Corporate Tax Structure
    • 14.1.11 Investments
    • 14.1.12 Major Companies
  • 14.2 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.3 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 Russia Market
  • 14.6 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.7 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.8 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

  • 15.1 Summary
    • 15.1.1 Market Overview
    • 15.1.2 Region Information
    • 15.1.3 Market Information
    • 15.1.4 Background Information
    • 15.1.5 Government Initiatives
    • 15.1.6 Regulations
    • 15.1.7 Regulatory Bodies
    • 15.1.8 Major Associations
    • 15.1.9 Taxes Levied
    • 15.1.10 Corporate Tax Structure
    • 15.1.11 Investments
    • 15.1.12 Major Companies
  • 15.2 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.3 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 North America Coronavirus (COVID-19) Current Therapy Market: Country Analysis
  • 15.6 USA Market
  • 15.7 Summary
    • 15.7.1 Market Overview
    • 15.7.2 Country Information
    • 15.7.3 Market Information
    • 15.7.4 Background Information
    • 15.7.5 Government Initiatives
    • 15.7.6 Regulations
    • 15.7.7 Regulatory Bodies
    • 15.7.8 Major Associations
    • 15.7.9 Taxes Levied
    • 15.7.10 Corporate Tax Structure
    • 15.7.11 Investments
    • 15.7.12 Major Companies
  • 15.8 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.10 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.11 Canada Market
  • 15.12 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.13 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.14 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

  • 16.1 Summary
    • 16.1.1 Market Overview
    • 16.1.2 Region Information
    • 16.1.3 Market Information
    • 16.1.4 Background Information
    • 16.1.5 Government Initiatives
    • 16.1.6 Regulations
    • 16.1.7 Regulatory Bodies
    • 16.1.8 Major Associations
    • 16.1.9 Taxes Levied
    • 16.1.10 Corporate Tax Structure
    • 16.1.11 Investments
    • 16.1.12 Major Companies
  • 16.2 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.3 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

  • 17.1 Summary
    • 17.1.1 Market Overview
    • 17.1.2 Region Information
    • 17.1.3 Market Information
    • 17.1.4 Background Information
    • 17.1.5 Government Initiatives
    • 17.1.6 Regulations
    • 17.1.7 Regulatory Bodies
    • 17.1.8 Major Associations
    • 17.1.9 Taxes Levied
    • 17.1.10 Corporate Tax Structure
    • 17.1.11 Investments
    • 17.1.12 Major Companies
  • 17.2 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.3 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

  • 18.1 Summary
    • 18.1.1 Market Overview
    • 18.1.2 Region Information
    • 18.1.3 Market Information
    • 18.1.4 Background Information
    • 18.1.5 Government Initiatives
    • 18.1.6 Regulations
    • 18.1.7 Regulatory Bodies
    • 18.1.8 Major Associations
    • 18.1.9 Taxes Levied
    • 18.1.10 Corporate Tax Structure
    • 18.1.11 Major Companies
  • 18.2 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.3 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.4 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape And Company Profiles

  • 19.1 Company Profiles
  • 19.2 Gilead Sciences, Inc
    • 19.2.1 Company Overview
    • 19.2.2 Products And Services
    • 19.2.3 Financial Overview
  • 19.3 Merck & Co., Inc.
    • 19.3.1 Company Overview
    • 19.3.2 Products And Services
    • 19.3.3 Business Strategy
    • 19.3.4 Financial Overview
  • 19.4 Regeneron Pharmaceuticals Inc
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
    • 19.4.3 Business Strategy
    • 19.4.4 Financial Overview
  • 19.5 F. Hoffman-La Roche Ltd
    • 19.5.1 Company Overview
    • 19.5.2 Products And Services
    • 19.5.3 Business Strategy
    • 19.5.4 Financial Overview
  • 19.6 Ipca Laboratories Limited
    • 19.6.1 Company Overview
    • 19.6.2 Products And Services
    • 19.6.3 Financial Overview

20 Other Major And Innovative Companies

  • 20.1 Zydus Group
    • 20.1.1 Company Overview
    • 20.1.2 Products and Services
  • 20.2 Sun Pharmaceutical Industries Limited
    • 20.2.1 Company Overview
    • 20.2.2 Products and Services
  • 20.3 AbbVie Inc
    • 20.3.1 Company Overview
    • 20.3.2 Products and Services
  • 20.4 Pfizer Inc
    • 20.4.1 Company Overview
    • 20.4.2 Products and Services
  • 20.5 Glenmark Pharmaceuticals Limited
    • 20.5.1 Company Overview
    • 20.5.2 Products and Services
  • 20.6 Eli Lilly and Company
    • 20.6.1 Company Overview
    • 20.6.2 Products and Services
  • 20.7 Sanofi SA
    • 20.7.1 Company Overview
    • 20.7.2 Products and Services
  • 20.8 GSK (GlaxoSmithKline)
    • 20.8.1 Company Overview
    • 20.8.2 Products and Services
  • 20.9 Novavax Inc
    • 20.9.1 Company Overview
    • 20.9.2 Products and Services
  • 20.10 AstraZeneca
    • 20.10.1 Company Overview
    • 20.10.2 Products and Services
  • 20.11 Johnson & Johnson
    • 20.11.1 Company Overview
    • 20.11.2 Products and Services
  • 20.12 Moderna Inc
    • 20.12.1 Company Overview
    • 20.12.2 Products and Services
  • 20.13 CureVac N.V.
    • 20.13.1 Company Overview
    • 20.13.2 Products and Services
  • 20.14 Wallace Pharmaceuticals, Inc
    • 20.14.1 Company Overview
    • 20.14.2 Products and Services
  • 20.15 Clover Biopharmaceuticals Ltd
    • 20.15.1 Company Overview
    • 20.15.2 Products and Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

  • 23.1 GSK Acquires CureVac
  • 23.2 FSII-Pardes Biosciences Merger Aims To Enhance COVID-19 Antiviral Therapy Capabilities

24 Opportunities And Strategies

  • 24.1 Global Coronavirus (COVID-19) Current Therapy Market In 2029 - Growth Strategies
    • 24.1.1 Market Trend Based Strategies
    • 24.1.2 Competitor Strategies

25 COVID-19 Current Therapy Market, Conclusions And Recommendations

  • 25.1 Conclusions
  • 25.2 Recommendations
    • 25.2.1 Product
    • 25.2.2 Place
    • 25.2.3 Price
    • 25.2.4 Promotion
    • 25.2.5 People

26 Appendix

  • 26.1 Geographies Covered
  • 26.2 Market Data Sources
  • 26.3 Research Methodology
  • 26.4 Currencies
  • 26.5 The Business Research Company
  • 26.6 Copyright and Disclaimer